We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain
Read MoreHide Full Article
We issued an updated research report on C. R. Bard Inc. on Mar 8, 2017. This leading supplier of healthcare products has gained prominence in the market with an expanding product portfolio and a series of regulatory approvals.
As a result, the company carries a Zacks Rank #2 (Buy), implying that the stock will overperform the broader U.S. equity market over the next one to three months.
C. R. Bard is a well-diversified company, providing a complete line of products to treat medical conditions through minimal invasive procedures in a cost-effective manner. Importantly, the company has a significant recurring revenue stream, as its products are primarily single-use. Moreover, the company hopes to achieve and maintain market leadership through its focus on four major product disease categories. About 76% of its products are either first or second in terms of market share, which is a significant positive in our view.
The Lutonix drug coated-balloon (DCB) is a flagship product of the company. It is an angioplasty balloon which is coated with a therapeutic dose of the drug paclitaxel, used to treat patients with peripheral arterial disease (PAD). The device is the first and only FDA-approved DCB in the U.S. The company anticipates accelerated sales of Lutonix DCB in other geographical regions to drive global growth in the peripheral PTA category. This will also boost top-line growth in the long run. The company is also a pioneer in the below-the-knee treatment space.
Additionally, C. R. Bard’s earnings yield is one of the highest among major Medical - Dental firms. The current earnings yield of 4.71% is higher than the 4.63% yield for the aforementioned sub-industry.
Share Price Performance
In the last one year, C. R. Bard outperformed the Zacks classified Medical/Dental-Supplies sub-industry with respect to price. The stock gained around 26.22%, while the industry rose 5.56% over the same time frame.
Further, earnings estimates have also been trending upward lately, reflecting optimism in the stock’s prospects. In the past 60 days, current-quarter and current-year estimates have moved north by 31.4% and 3.5%, respectively. Stocks to Consider
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock has an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. In addition, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain
We issued an updated research report on C. R. Bard Inc. on Mar 8, 2017. This leading supplier of healthcare products has gained prominence in the market with an expanding product portfolio and a series of regulatory approvals.
.jpg)
As a result, the company carries a Zacks Rank #2 (Buy), implying that the stock will overperform the broader U.S. equity market over the next one to three months.
C. R. Bard is a well-diversified company, providing a complete line of products to treat medical conditions through minimal invasive procedures in a cost-effective manner. Importantly, the company has a significant recurring revenue stream, as its products are primarily single-use. Moreover, the company hopes to achieve and maintain market leadership through its focus on four major product disease categories. About 76% of its products are either first or second in terms of market share, which is a significant positive in our view.
The Lutonix drug coated-balloon (DCB) is a flagship product of the company. It is an angioplasty balloon which is coated with a therapeutic dose of the drug paclitaxel, used to treat patients with peripheral arterial disease (PAD). The device is the first and only FDA-approved DCB in the U.S. The company anticipates accelerated sales of Lutonix DCB in other geographical regions to drive global growth in the peripheral PTA category. This will also boost top-line growth in the long run. The company is also a pioneer in the below-the-knee treatment space.
Additionally, C. R. Bard’s earnings yield is one of the highest among major Medical - Dental firms. The current earnings yield of 4.71% is higher than the 4.63% yield for the aforementioned sub-industry.
Share Price Performance
In the last one year, C. R. Bard outperformed the Zacks classified Medical/Dental-Supplies sub-industry with respect to price. The stock gained around 26.22%, while the industry rose 5.56% over the same time frame.
Further, earnings estimates have also been trending upward lately, reflecting optimism in the stock’s prospects. In the past 60 days, current-quarter and current-year estimates have moved north by 31.4% and 3.5%, respectively.
Stocks to Consider
Some other better-ranked stocks in the sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock has an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. In addition, the company posted a positive earnings surprise of 27% last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% last quarter.
8 Stocks with Huge Profit Potential
Just released: Driverless Cars: Your Roadmap to Mega-Profits Today. In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>